Teva has announced a major strategic shift in Japan, involving plans to change the focus of its joint business venture with Takeda and divest a significant chunk of the unit’s generics business to Nichi-Iko.
“Nearly five years since its inception, and following an in-depth review of market opportunities,” Teva said, “the BV’s new strategy...




